How to buy AMAG Pharmaceuticals stock

AMAG Pharmaceuticals Inc is a biotechnology business based in the US. AMAG Pharmaceuticals shares (AMAG) are listed on the NASDAQ and all prices are listed in US Dollars. AMAG Pharmaceuticals employs 440 staff and has a trailing 12-month revenue of around 0.00.

AMAG Pharmaceuticals stock price (NASDAQ: AMAG)

Use our graph to track the performance of AMAG stocks over time.

AMAG Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-01-22.

52-week range	$13.61 - $13.76
50-day moving average	$13.72
200-day moving average	$10.32
Wall St. target price	$11.96
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-6.83

Buy AMAG Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy AMAG Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is AMAG Pharmaceuticals under- or over-valued?

Valuing AMAG Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AMAG Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AMAG Pharmaceuticals's PEG ratio

AMAG Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.32. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AMAG Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

AMAG Pharmaceuticals financials

Revenue TTM	$300.1 million
Gross profit TTM	$219.4 million
Return on assets TTM	-3.06%
Return on equity TTM	0%
Profit margin	-77.18%
Book value	$7.42
Market capitalisation	$477.5 million

TTM: trailing 12 months

Shorting AMAG Pharmaceuticals shares

There are currently 6.3 million AMAG Pharmaceuticals shares held short by investors – that's known as AMAG Pharmaceuticals's "short interest". This figure is 13% down from 7.2 million last month.

There are a few different ways that this level of interest in shorting AMAG Pharmaceuticals shares can be evaluated.

AMAG Pharmaceuticals's "short interest ratio" (SIR)

AMAG Pharmaceuticals's "short interest ratio" (SIR) is the quantity of AMAG Pharmaceuticals shares currently shorted divided by the average quantity of AMAG Pharmaceuticals shares traded daily (recently around 3.4 million). AMAG Pharmaceuticals's SIR currently stands at 1.83. In other words for every 100,000 AMAG Pharmaceuticals shares traded daily on the market, roughly 1830 shares are currently held short.

However AMAG Pharmaceuticals's short interest can also be evaluated against the total number of AMAG Pharmaceuticals shares, or, against the total number of tradable AMAG Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AMAG Pharmaceuticals's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 AMAG Pharmaceuticals shares in existence, roughly 180 shares are currently held short) or 0.3803% of the tradable shares (for every 100,000 tradable AMAG Pharmaceuticals shares, roughly 380 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AMAG Pharmaceuticals.

Find out more about how you can short AMAG Pharmaceuticals stock.

AMAG Pharmaceuticals share dividends

We're not expecting AMAG Pharmaceuticals to pay a dividend over the next 12 months.

Have AMAG Pharmaceuticals's shares ever split?

AMAG Pharmaceuticals's shares were split on a 3:2 basis on 25 September 1991. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your AMAG Pharmaceuticals shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for AMAG Pharmaceuticals shares which in turn could have impacted AMAG Pharmaceuticals's share price.

AMAG Pharmaceuticals share price volatility

Over the last 12 months, AMAG Pharmaceuticals's shares have ranged in value from as little as $13.61 up to $13.76. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AMAG Pharmaceuticals's is 0.8675. This would suggest that AMAG Pharmaceuticals's shares are less volatile than average (for this exchange).

AMAG Pharmaceuticals overview

AMAG Pharmaceuticals, Inc. , a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc. , Palatin Technologies, Inc.

Frequently asked questions

What percentage of AMAG Pharmaceuticals is owned by insiders or institutions?
Currently 2.287% of AMAG Pharmaceuticals shares are held by insiders and 101.079% by institutions. How many people work for AMAG Pharmaceuticals?
Latest data suggests 440 work at AMAG Pharmaceuticals. When does the fiscal year end for AMAG Pharmaceuticals?
AMAG Pharmaceuticals's fiscal year ends in December. Where is AMAG Pharmaceuticals based?
AMAG Pharmaceuticals's address is: 1100 Winter Street, Waltham, MA, United States, 02451 What is AMAG Pharmaceuticals's ISIN number?
AMAG Pharmaceuticals's international securities identification number is: US00163U1060 What is AMAG Pharmaceuticals's CUSIP number?
AMAG Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 00163U106